help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by KHOUKAZ, G.
Right arrow Articles by GROSS, N. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KHOUKAZ, G.
Right arrow Articles by GROSS, N. J.

Am. J. Respir. Crit. Care Med., Volume 160, Number 3, September 1999, 1028-1030

Effects of Salmeterol on Arterial Blood Gases in Patients with Stable Chronic Obstructive Pulmonary Disease
Comparison with Albuterol and Ipratropium

GHASSAN KHOUKAZ and NICHOLAS J. GROSS

Division of Pulmonary and Critical Medicine, Hines Veterans Affairs Hospital, Hines; and Department of Medicine, Stritch School of Medicine, Loyola University of Chicago, Maywood, Illinois

Administration of beta -adrenergic agonist bronchodilators to patients with airways obstruction commonly results in transient decreases in PaO2 levels despite bronchodilation, an effect that has been attributed to these drugs' pulmonary vasodilator action. We compared the acute effects on gas exchange of salmeterol with those of albuterol and the anticholinergic agent ipratropium in 20 patients with stable chronic obstructive pulmonary disease (COPD). Each agent was given in recommended dosage on separate days in a double-blind, crossover format, and the patients' arterial blood gases (ABGs) were measured at baseline and at intervals to 120 min. Small but statistically significant declines in PaO2, the primary outcome variable, were found after administration of both salmeterol and albuterol. The decline in PaO2 after salmeterol was of lesser magnitude but was more prolonged than that after albuterol, the greatest mean change being -2.74 ± 0.89 mm Hg (mean ± SEM) at 30 min after salmeterol, and -3.45 ± 0.92 mm Hg at 20 min after albuterol. Following ipratropium, the corresponding change was -1.32 ± 0.85 mm Hg at 20 min. These declines, which were almost entirely attributable to increases in the alveolar-arterial difference in oxygen tension Delta (A-a)DO2 tended to be more marked in subjects with higher baseline PaO2 values. No subject experienced a decline in PaO2 to levels below 59 mm Hg. There were no significant differences among the three drugs studied. We conclude that despite small decreases in PaO2 after each of the three drugs, the declines were small, transient, and of doubtful clinical significance.




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
G. F. Joos
Are beta2-Agonists Safe in Patients with Acute Exacerbations of COPD?
Am. J. Respir. Crit. Care Med., August 15, 2007; 176(4): 322 - 323.
[Full Text] [PDF]

Home page
 ThoraxHome page
R Rodriguez-Roisin
COPD exacerbations {middle dot} 5: Management.
Thorax, June 1, 2006; 61(6): 535 - 544.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
N. J. Gross
Tiotropium Bromide
Chest, December 1, 2004; 126(6): 1946 - 1953.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
J. A Dougherty, B. L Didur, and L. S Aboussouan
Long-Acting Inhaled {beta}2-Agonists for Stable COPD
Ann. Pharmacother., September 1, 2003; 37(9): 1247 - 1255.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1999 American Thoracic Society